Anaphylaxis News and Research

RSS
Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.
Grifols receives FDA approval for Alphanate to treat vCJD

Grifols receives FDA approval for Alphanate to treat vCJD

Scientists devise new on-line calculator to predict food allergies in children

Scientists devise new on-line calculator to predict food allergies in children

Experts offer myth-busting advice to fight against spring allergies

Experts offer myth-busting advice to fight against spring allergies

AMAG fourth quarter total revenues increase to $17.2 million

AMAG fourth quarter total revenues increase to $17.2 million

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

New guidelines recommend routine use of allergy tests to improve quality of care in children

New guidelines recommend routine use of allergy tests to improve quality of care in children

ASC launches ACT NOW to offer support, education about asthma and respiratory allergies

ASC launches ACT NOW to offer support, education about asthma and respiratory allergies

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

Dermatologists advise parents of young children about atopic dermatitis, food allergies

Dermatologists advise parents of young children about atopic dermatitis, food allergies

Canadian government urged to approve proposed federal food labelling regulations

Canadian government urged to approve proposed federal food labelling regulations

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Anaphylaxis through the eyes of the food-allergic child

Anaphylaxis through the eyes of the food-allergic child

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

DBV Technologies secures $25.5 million in Series C financing round

DBV Technologies secures $25.5 million in Series C financing round

Meda gains exclusive marketing and distribution rights for EpiPen Auto-Injector in Europe

Meda gains exclusive marketing and distribution rights for EpiPen Auto-Injector in Europe

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

Official guidelines for diagnosis, treatment and management of food allergies released

Official guidelines for diagnosis, treatment and management of food allergies released

New NIH guidelines support broader use of blood tests to diagnose food allergy

New NIH guidelines support broader use of blood tests to diagnose food allergy